Denecimig excels at reducing bleeds in hemophilia A patients: Study
WHY IT MATTERS
If denecimig gains approval, hemophilia A patients—especially those with inhibitors who have limited treatment options—could switch to a once-monthly injection that reduces bleeds more effectively than their current preventive regimens.
A new medicine called denecimig (Mim8) was tested in a study called FRONTIER2 and worked better than current treatments at stopping bleeding episodes in people with hemophilia A. The medicine was given either once a month or once a week, and it worked well for both adults and teenagers 12 years and older, even for patients whose bodies have developed resistance to other treatments.
Denecimig (Mim8) was significantly better than on-demand or standard preventive treatments at reducing bleeding episodes in people with hemophilia A, regardless of inhibitor status. That’s according to published data from the FRONTIER2 trial (NCT05053139), which evaluated the efficacy and safety of once-monthly and once-weekly denecimig treatment in adults and adolescents ages 12 years and older with […] The post Denecimig excels at reducing bleeds in hemophilia A patients: Study appeared
ASK YOUR DOCTOR
Ask your hematologist if denecimig might be appropriate for you once it becomes available, particularly if you currently use on-demand or standard preventive treatments.